| scholarly article | Q13442814 |
| P50 | author | Chalermrat Bunchorntavakul | Q89704743 |
| Tawesak Tanwandee | Q114366716 | ||
| P2093 | author name string | Disaya Chavalitdhamrong | |
| P2860 | cites work | Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 |
| An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases | Q24632766 | ||
| Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions | Q27477772 | ||
| Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV Assay | Q27478358 | ||
| Genotypic distribution of hepatitis C virus in different regions of Thailand | Q27485781 | ||
| Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0 | Q27486402 | ||
| Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes | Q27861119 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| The global burden of hepatitis C | Q29620138 | ||
| Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | Q29620702 | ||
| A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt | Q30403548 | ||
| Discussing depression with Vietnamese American patients | Q33731313 | ||
| Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans | Q33977173 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 | ||
| Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. | Q34801283 | ||
| Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population | Q35638812 | ||
| Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. | Q36290096 | ||
| HCV-related autoimmune and neoplastic disorders: the HCV syndrome | Q36971042 | ||
| Hepatitis C virus-induced cryoglobulinemia | Q37371397 | ||
| Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects | Q37561259 | ||
| IL28B single nucleotide polymorphisms in the treatment of hepatitis C. | Q37858161 | ||
| Systematic review: epidemiology of hepatitis C genotype 6 and its management | Q37882006 | ||
| New therapeutic strategies in HCV: second-generation protease inhibitors | Q38071391 | ||
| New therapeutic strategies in HCV: polymerase inhibitors | Q38071392 | ||
| Systematic review: Asian patients with chronic hepatitis C infection | Q38096012 | ||
| APASL consensus statements and management algorithms for hepatitis C virus infection. | Q38552131 | ||
| Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong | Q40340560 | ||
| Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). | Q42287037 | ||
| A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. | Q42633156 | ||
| Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin | Q42978398 | ||
| Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong | Q42980131 | ||
| Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study | Q42980225 | ||
| Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany | Q42980355 | ||
| Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa | Q42981557 | ||
| Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. | Q42985033 | ||
| Analysis of HCV genotypes from blood donors shows three new HCV type 6 subgroups exist in Myanmar | Q42988064 | ||
| High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong | Q42990073 | ||
| Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial | Q42990184 | ||
| Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants | Q42990760 | ||
| High prevalence of Hepatitis C virus genotype 6 in Vietnam | Q42991817 | ||
| Genotypic distribution of hepatitis C virus in voluntary blood donors of northern Thailand. | Q42991869 | ||
| Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. | Q42993494 | ||
| Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand | Q42993738 | ||
| Natural history of chronic hepatitis C: genotype 1 versus genotype 6. | Q42997765 | ||
| Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes | Q42998461 | ||
| Seroprevalence and genotype of hepatitis C virus among immigrant workers from Cambodia and Myanmar in Thailand | Q42999055 | ||
| Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6 | Q43001193 | ||
| Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. | Q43001742 | ||
| The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6. | Q43036492 | ||
| Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome | Q43040635 | ||
| High genetic diversity including potential new subtypes of hepatitis C virus genotype 6 in Lao People's Democratic Republic | Q43040928 | ||
| Seroepidemiology and genotypes of hepatitis C virus in Thailand. | Q43042352 | ||
| Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. | Q43049104 | ||
| Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. | Q43244698 | ||
| The emerging importance of chronic hepatitis C infection in Asian Americans. | Q44600956 | ||
| Hepatitis C virus genotype distribution in Myanmar: Predominance of genotype 6 and existence of new genotype 6 subtype | Q45405039 | ||
| A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. | Q50532082 | ||
| Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. | Q50559664 | ||
| Iron deficiency in pregnant women in Ibarapa District of Western Nigeria. | Q50716575 | ||
| Hepatitis C--global prevalence (update) | Q73379666 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 496-504 | |
| P577 | publication date | 2013-09-27 | |
| P1433 | published in | World Journal of Hepatology | Q27723328 |
| P1476 | title | Hepatitis C genotype 6: A concise review and response-guided therapy proposal | |
| P478 | volume | 5 |
| Q26828972 | Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6 |
| Q36095525 | Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. |
| Q35194590 | Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis |
| Q92134698 | Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature |
| Q64102796 | Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial |
| Q40229053 | HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis |
| Q39285786 | Hepatitis C virus genotypes in Kenya |
| Q34008754 | Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy |
| Q38247985 | Simeprevir for the treatment of hepatitis C virus infection |
| Q59808283 | Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China |
| Q92275982 | Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience |
| Q35270937 | Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis |
Search more.